CHA-CHING!

This is how many Houston workers now earn 6-figure salaries

Some Houston workers are earning the big bucks. PaidSurveysHQ.org

As one of the biggest opportunity cities in the U.S., the Houston area presents an opportunity for workers to cash in.

From 2015 to 2020, Houston saw a 21.9-percent increase in six-figure jobs. In our region, 8.8 percent of jobs pay at least $100,000 a year, according to a new study from Stessa, a provider of property management software for landlords.

That's the highest percentage among the four major metros in Texas, for reference (and for bragging rights).

Across the metro area, the median annual pay stands at $42,710.

Nationally, professions that often draw at least $100,000 a year include software developer, attorney, sales manager, pharmacist, and nurse practitioner, according to the study.

"One of the COVID-19 pandemic's most significant long-term effects on the economy could be rising wages," the study says. "With widespread shortages in the labor market reported this summer, many employers — particularly those with lower-wage employees — have tried to entice workers with improved compensation and benefits. These trends have led to the fastest rates of wage growth since the Great Recession, especially among the lowest earners."

Among large metro areas, Nashville ranks first for the growth of six-figure jobs from 2015 to 2020 — 270.9 percent.

Looking at major Texas metro areas in Texas, San Antonio claims the highest ranking for growth in six-figure jobs: No. 7. From 2015 to 2020, the share of six-figure jobs in the San Antonio area went up by 163 percent. Last year, 5.7 percent of jobs in San Antonio pulled in at least $100,000 annually.

DFW saw a 60 percent rise in six-figure jobs. In DFW, 8.5 percent of workers — or 306,240 people — earn six-figure salaries, the study says.

Austin holds the No. 15 spot among major metro areas, with a 101.1 percent jump in six-figure jobs from 2015 to 2020. Last year, 7.6 percent of jobs in the Austin area raked in at least $100,000 annually.

------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News